Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S, Wei AH, Carroll M, Goubard A, Castellano R, Collette Y, Vergez F, Mansat-De Mas V, Bertoli S, Tavitian S, Picard M, Récher C, Bourges-Abella N, Granat F, Kosmider O, Sujobert P, Colsch B, Joffre C, Stuani L, Swinnen JV, Guillou H, Roué G, Hakim N, Dejean AS, Tsantoulis P, Larrue C, Bouscary D, Tamburini J, Sarry JE. Sabatier M, et al. Among authors: heiblig m. Cancer Discov. 2023 Jul 7;13(7):1720-1747. doi: 10.1158/2159-8290.CD-22-0411. Cancer Discov. 2023. PMID: 37012202
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE. Heiblig M, et al. Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5. Exp Hematol. 2018. PMID: 30195076 Free article.
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters.
Bruch PM, Dietrich S, Finel H, Boumendil A, Greinix H, Heinicke T, Bethge W, Beelen D, Schmid C, Martin H, Castagna L, Scheid C, Schäfer-Eckart K, Bittenbring J, Finke J, Sengeloev H, Heiblig M, Cornelissen J, Chevallier P, Mohty M, Robinson S, Montoto S, Dreger P. Bruch PM, et al. Among authors: heiblig m. Leukemia. 2023 Feb;37(2):465-472. doi: 10.1038/s41375-022-01782-z. Epub 2022 Dec 22. Leukemia. 2023. PMID: 36550212
VEXAS: where do we stand 2 years later?
Sujobert P, Heiblig M, Jamilloux Y. Sujobert P, et al. Among authors: heiblig m. Curr Opin Hematol. 2023 Mar 1;30(2):64-69. doi: 10.1097/MOH.0000000000000750. Epub 2022 Dec 30. Curr Opin Hematol. 2023. PMID: 36728604 Review.
Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome.
Faurel A, Heiblig M, Kosmider O, Cornillon J, Boudou L, Guyotat D, Martignoles JA, Jamilloux Y, Noyel P, Daguenet E, Faure AC, Sujobert P, Flandrin-Gresta P. Faurel A, et al. Among authors: heiblig m. Hemasphere. 2023 Mar 24;7(4):e868. doi: 10.1097/HS9.0000000000000868. eCollection 2023 Apr. Hemasphere. 2023. PMID: 36999004 Free PMC article. No abstract available.
71 results